EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Similar Posts
EyeCRO scientist contributes to a paper published in Experimental Eye Research
EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor
EyeCRO CEO Rafal Farjo Named ARVO Foundation Chair
We are excited to announce that our CEO, Rafal Farjo, Ph.D., has been named the ARVO Foundation for Eye Research Chair. This prestigious appointment highlights Dr. Farjo’s extensive experience and dedication to advancing ocular research over the past 25 years. As the CEO of EyeCRO, Dr. Farjo has been instrumental in helping clients develop new…
EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™
EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…
EyeCRO Receives Full Accreditation from AAALAC International for its Research Facilities
EyeCRO LLC has been awarded full accreditation from AAALAC International for their facility in Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical Research Foundation, Oklahoma State University, and the University of Oklahoma Health Sciences Center as the fifth institution in Oklahoma to receive this prestigious endorsement. The award letter from…
Once-daily CsA-MiDROPS™ are superior to other CsA drops dosed twice-daily
Ophthalmic distribution studies indicate significantly increased drug concentration with CsA-MiDROPS (Cyclosporine A microemulsion) compared with Restasis. CsA-MiDROPS is well tolerated with little toxicity in a 2-week tolerability study. In the DED model, both 0.05% and 0.1% CsA-MiDROPS conferred a significant effect and were more effective than Restasis for treating experimental DED when dosed twice per…
EyeCRO scientists contribute to study published in Nature
“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The work, funded by the National Eye Institute (NEI), published April 15 in Nature.” (Click here to read rest of article)
